2',3',5'-三脱氧腺苷 | 6612-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 2',3',5'-三脱氧腺苷
• 中文别名: 去羟肌苷杂质
• 英文名称: 2',3',5'-Trideoxyadenosin
• 英文别名: 2',3',5'-Tridesoxy-adenosin；9-(5-methyl-tetrahydro-furan-2-yl)-9H-purin-6-ylamine；2',3',5'-Trideoxyadenosine；9-[(2R,5R)-5-methyloxolan-2-yl]purin-6-amine
• CAS: 6612-70-0
• 化学式: C₁₀H₁₃N₅O
• 分子量: 219.246
• InChiKey: PSPPXRNUZVTTON-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Prodrugs Activated by Rna-Dependent Dna-Polymerases
  申请人：Bertini Ivano

  公开号：US20080300215A1

  公开（公告）日：2008-12-04

  Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses.

  本发明描述了由RNA依赖的DNA聚合酶（如端粒酶和逆转录病毒酶）激活的前药，它们用于治疗血液肿瘤以及受逆转录病毒感染的患者的血液和血液衍生物，并用于制备药物组合物，用于治疗实体肿瘤、癌前状态和由逆转录病毒感染引起的疾病。
• Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxycytidine
  申请人：THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce

  公开号：EP0216511A2

  公开（公告）日：1987-04-01

  The present invention relates to a method of alleviating the cytopathic effects of HTLV-III virus on cells which comprises contacting the virus with an effec­tive amount of at least one of 2',3'-dideoxycytidine and its mono- and triphosphates.

  本发明涉及一种减轻 HTLV-III 病毒对细胞的细胞病理效应的方法，该方法包括将病毒与有效量的 2'，3'-二脱氧胞苷及其单磷酸和三磷酸中的至少一种接触。
• Antiviral agents
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0371366A1

  公开（公告）日：1990-06-06

  Nucleoside compounds of the formula wherein: B is guanine, adenine, thymine, uracil, cytosine, hypoxanthine, xanthine, 5-methylcytosine, 4-ethoxy-5-methyl-2-oxo-pyrimidine, 4-isopropoxy-5-methyl-2-oxo-pyrimidine, or 5-methyl-2-oxo-pyrimidine; X isHorF; Y is H, OH, OCH3 or F; and Z is where n is zero, one, or three and both R are hydrogen or lower alkyl; or Y and Z together form a cyclic phosphate ester; and the pharmaceutically acceptable esters, ethers and salts thereof, have been found to have potent antiviral activity with a high therapeutic ratio.

  式中的核苷化合物 其中 B 是鸟嘌呤、腺嘌呤、胸腺嘧啶、尿嘧啶、胞嘧啶、次黄嘌呤、黄嘌呤、5-甲基胞嘧啶、4-乙氧基-5-甲基-2-氧代嘧啶、4-异丙氧基-5-甲基-2-氧代嘧啶或 5-甲基-2-氧代嘧啶； X 是 H 或 F； Y 是 H、OH、OCH3 或 F；以及 Z 是 其中 n 为 0、1 或 3，两个 R 均为氢或低级烷基；或 Y 和 Z 共同形成环磷酸酯；已发现这些药学上可接受的酯、醚和盐具有很强的抗病毒活性和很高的治疗比例。
• Detection, monitoring and treatment of cancer
  申请人：THE OPEN UNIVERSITY

  公开号：EP1806585A1

  公开（公告）日：2007-07-11

  There are disclosed compounds having the structure: wherein R1, R2, R3 are each independently: hydrogen, R4, R5, R5-carbonyl, R5-sulphonyl; R4 comprises an amino acid moiety; R5 is: alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, wherein each of these groups is optionally substituted by one or more of: alkyl, amino, amino-carbonyl, amino-sulphonyl, halo, cyano, hydroxy, nitro, trifluoromethyl, alkoxy, alkoxycarbonyl, aryl and alkylthio; and salts and solvates thereof.

  已公开的化合物具有以下结构： 其中 R1、R2、R3 各自独立： 氢、R4、R5、R5-羰基、R5-磺酰基； R4 包括氨基酸分子； R5 是 烷基、烯基、炔基、环烷基、芳基、杂芳基、杂环烷基，其中每个基团任选被一个或多个基团取代： 烷基、氨基、氨基羰基、氨基磺酰基、卤代、氰基、羟基、硝基、三氟甲基、烷氧基、烷氧羰基、芳基和烷硫基； 及其盐类和溶剂。
• Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine
  申请人：THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce

  公开号：EP0216510B1

  公开（公告）日：1993-10-27